Payers and the assessment of clinical utility for companion diagnostics

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 6, 2010, Pages 751-754

  Quinn, B ^a  

^a Government Affairs/Life Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH SERVICE; PRIORITY JOURNAL; REIMBURSEMENT; SHORT SURVEY;

DECISION MAKING; DIAGNOSTIC TEST APPROVAL; HUMANS; INDIVIDUALIZED MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 78449302916     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.234     Document Type: Short Survey

References (7)

1. Teutsch, S.M. et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP working group. Genet. Med. 11, 3-14 (2009).
2. Michael, C.M. & Ball, J.R., eds. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (Institute of Medicine, National Academies Press, Washington, DC, 2010).
3. Ramsay, S.D. et al. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. Am. J. Manag. Care 12, 197-202 (2006).
4. Goodman, S., Dickerson, K. & Wilson, R. Effectiveness Guidance Document: Gene Expression Tests for Early Stage Breast Cancer. Center for Medical Technology Policy, Baltimore, MD (June 2009).
5. Ouellet, D. Benefit-risk assessment: the use of a clinical utility index. Expert Opin. Drug Saf. 9, 289-300 (2010).
6. Aetna. Clinical Policy Bulletin: Pharmacogenetic and Pharmacodynamic Testing Accessed 20 August 2010.
7. Center for Medicare and Medicaid Services. Decision Memo for Pharmacogenomic Testing for Warfarin Response (CAG-00400N) Accessed 20 August 2010.